Theravance Biopharma Stock Probability of Future Stock Price Finishing Over 11.53
| TBPH Stock | USD 9.47 0.14 1.46% |
Theravance |
Theravance Biopharma Target Price Odds to finish over 11.53
The tendency of Theravance Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 11.53 or more in 90 days |
| 9.47 | 90 days | 11.53 | near 1 |
Based on a normal probability distribution, the odds of Theravance Biopharma to move over $ 11.53 or more in 90 days from now is near 1 (This Theravance Biopharma probability density function shows the probability of Theravance Stock to fall within a particular range of prices over 90 days) . Probability of Theravance Biopharma price to stay between its current price of $ 9.47 and $ 11.53 at the end of the 90-day period is roughly 2.96 .
Given the investment horizon of 90 days Theravance Biopharma has a beta of 0.95. This usually implies Theravance Biopharma market returns are responsive to returns on the market. As the market goes up or down, Theravance Biopharma is expected to follow. Additionally Theravance Biopharma has an alpha of 0.1492, implying that it can generate a 0.15 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Theravance Biopharma Price Density |
| Price |
Predictive Modules for Theravance Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Theravance Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Theravance Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Theravance Biopharma is not an exception. The market had few large corrections towards the Theravance Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Theravance Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Theravance Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.15 | |
β | Beta against Dow Jones | 0.95 | |
σ | Overall volatility | 0.53 | |
Ir | Information ratio | 0.07 |
Theravance Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Theravance Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Theravance Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Theravance Biopharma has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 57.42 M. Net Loss for the year was (55.19 M) with loss before overhead, payroll, taxes, and interest of (12.05 M). | |
| Theravance Biopharma currently holds about 132.85 M in cash with (27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Disposition of 9178 shares by Rhonda Farnum of Theravance Biopharma at 9.97 subject to Rule 16b-3 |
Theravance Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Theravance Stock often depends not only on the future outlook of the current and potential Theravance Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Theravance Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 55.3 M | |
| Cash And Short Term Investments | 102.4 M |
Theravance Biopharma Technical Analysis
Theravance Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Theravance Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Theravance Biopharma. In general, you should focus on analyzing Theravance Stock price patterns and their correlations with different microeconomic environments and drivers.
Theravance Biopharma Predictive Forecast Models
Theravance Biopharma's time-series forecasting models is one of many Theravance Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Theravance Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Theravance Biopharma
Checking the ongoing alerts about Theravance Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Theravance Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Theravance Biopharma has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 57.42 M. Net Loss for the year was (55.19 M) with loss before overhead, payroll, taxes, and interest of (12.05 M). | |
| Theravance Biopharma currently holds about 132.85 M in cash with (27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Disposition of 9178 shares by Rhonda Farnum of Theravance Biopharma at 9.97 subject to Rule 16b-3 |
Check out Theravance Biopharma Backtesting, Theravance Biopharma Valuation, Theravance Biopharma Correlation, Theravance Biopharma Hype Analysis, Theravance Biopharma Volatility, Theravance Biopharma History as well as Theravance Biopharma Performance. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.03) | Revenue Per Share 1.293 | Quarterly Revenue Growth 0.075 | Return On Assets (0.06) | Return On Equity (0.23) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.